Cabergoline

Generic Name: Cabergoline

Brand Names: Dostinex

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₇N_₅O_₂

CAS Number: 81409-90-7

Unique Ingredient Identifier: LL60K9J05T

Background: Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

Indication: For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.

Associated Conditions: Hyperprolactinemia, Idiopathic hyperprolactinemic disorder

Associated Therapies: Inhibition of physiological lactation

Clinical Trials

Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Conditions: OHSS

Interventions: Drug: GnRH antagonist rescue & cabergoline
Drug: Cabergoline

First Posted Date: 2015-06-03

Last Posted Date: 2015-11-17

Lead Sponsor: Aljazeera Hospital

Target Recruit Count: 236

Registration Number: NCT02461875

Locations: 🇪🇬
Aljazeera( Al Gazeera) hospital, Giza, Egypt

Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection

Phase 2

Conditions: Infertility

Interventions: Drug: Cabergoline

First Posted Date: 2014-12-03

Last Posted Date: 2016-12-06

Lead Sponsor: Kasr El Aini Hospital

Target Recruit Count: 150

Registration Number: NCT02306564

Locations: 🇪🇬
Assissted reproduction unit Kasr alaini hospital, Garden city, Cairo, Egypt

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

Phase 3

Recruiting

Conditions: Pituitary Neoplasms
Adenoma

Interventions: Drug: cabergoline

First Posted Date: 2014-11-13

Last Posted Date: 2024-06-04

Lead Sponsor: St. Olavs Hospital

Target Recruit Count: 60

Registration Number: NCT02288962

Locations: 🇳🇴
Department of Endocrinology, Akershus University hospital, Oslo, Norway
🇸🇪
Sahlgrenska University Hospital, Gøteborg, Sweden
🇳🇴
Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway

Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Calcium Dobesilate
Drug: Cabergoline

First Posted Date: 2014-10-22

Last Posted Date: 2017-02-16

Lead Sponsor: Benha University

Target Recruit Count: 200

Registration Number: NCT02271360

Locations: 🇪🇬
Benha univesity hospital, Benha, El Qualyobia, Egypt

Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Diosmin
Drug: Cabergoline

First Posted Date: 2014-05-09

Last Posted Date: 2016-02-02

Lead Sponsor: Benha University

Target Recruit Count: 200

Registration Number: NCT02134249

Locations: 🇪🇬
Benha univesity hospital, Benha, El Qualyobia, Egypt
🇪🇬
Banha Universty, Banha, El Qalubia, Egypt

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4

Completed

Conditions: Acromegaly
Pituitary Tumors
Ectopic ACTH Secreting (EAS) Tumors
Melanoma Negative for bRAF
Cushing's Disease
Neuroendocrine Tumors
Prostate Cancer
Melanoma Negative for nRAS
Dumping Syndrome

Interventions: Drug: Pasireotide
Drug: Pasireotide LAR
Drug: Cabergoline

First Posted Date: 2013-02-20

Last Posted Date: 2024-10-01

Lead Sponsor: RECORDATI GROUP

Target Recruit Count: 337

Registration Number: NCT01794793

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States
🇮🇹
Milano Investigative Site, Milano, MI, Italy
🇺🇸
Ximed Research SC - SOM230B2412, La Jolla, California, United States

and more 6 locations

Cabergoline in Metastatic Breast Cancer

Early Phase 1

Completed

Conditions: Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: cabergoline

First Posted Date: 2012-11-21

Last Posted Date: 2019-09-17

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT01730729

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

Phase 1

Completed

Conditions: Cocaine Dependence
Cocaine Abuse
Cocaine Addiction
Substance Abuse

Interventions: Drug: Placebo
Drug: Cabergoline

First Posted Date: 2012-07-27

Last Posted Date: 2012-07-27

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 11

Registration Number: NCT01651364

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Phase 2

Completed

Conditions: Non-functioning Pituitary Adenomas
Prolactinomas

Interventions: Drug: Pasireotide
Drug: cabergoline

First Posted Date: 2012-06-15

Last Posted Date: 2016-08-22

Lead Sponsor: Universidade Federal do Rio de Janeiro

Target Recruit Count: 21

Registration Number: NCT01620138

Locations: 🇧🇷
Endocrinology Section - Hospital Universitário Clementino Fraga Filho/Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Ovarian Hyperstimulation Syndrome and Cabergoline

Not Applicable

Completed

Conditions: Polycystic Ovarian Syndrome
Ovarian Hyperstimulation Syndrome

Interventions: Drug: Cabergoline

First Posted Date: 2012-04-03

Last Posted Date: 2012-04-04

Lead Sponsor: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital

Target Recruit Count: 40

Registration Number: NCT01569256

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy